In a patient with B‑cell acute lymphoblastic leukemia (ALL) and an absolute neutrophil count (ANC) of 200 cells/µL, what antibiotic prophylaxis is recommended?

Fluoroquinolone Prophylaxis Recommended

For a B-cell ALL patient with an ANC of 200 cells/µL, fluoroquinolone prophylaxis (levofloxacin or ciprofloxacin) should be initiated, as this patient meets criteria for high-risk neutropenia with profound immunosuppression. 1, 2

Risk Assessment

Your patient clearly falls into the high-risk category based on:

• ANC of 200 cells/µL (well below the 500 threshold, approaching the <100 threshold for profound neutropenia)
• B-cell ALL diagnosis - a hematologic malignancy with inherently prolonged neutropenia expected >7 days
• Expected duration - ALL treatment typically causes neutropenia lasting well beyond 7 days

The IDSA guidelines explicitly state that fluoroquinolone prophylaxis should be considered for high-risk patients with expected durations of prolonged and profound neutropenia (ANC <100 cells/mm³ for >7 days) 1, 2. While your patient's ANC is currently 200, B-cell ALL patients routinely experience profound and prolonged neutropenia during treatment phases.

Specific Antibiotic Recommendations

Primary choice:

• Levofloxacin is preferred over ciprofloxacin in B-cell ALL patients 1, 2
  • Better coverage for viridans group streptococcal infections
  • B-cell ALL patients receiving intensive chemotherapy are at increased risk for oral mucositis-related invasive streptococcal infections
  • Both agents are considered roughly equivalent otherwise, but levofloxacin has this specific advantage

Alternative if levofloxacin unavailable:

• Ciprofloxacin is acceptable 1

Do NOT add:

• Gram-positive active agents (e.g., vancomycin) to fluoroquinolone prophylaxis - this is explicitly not recommended 1, 2

Duration of Prophylaxis

Continue fluoroquinolone prophylaxis:

• Throughout the period of neutropenia
• Until ANC recovers to >500 cells/mm³ with a consistent increasing trend 1
• If an infection develops and is treated successfully, patients who remain neutropenic may resume oral fluoroquinolone prophylaxis until marrow recovery 1

Critical Monitoring Requirements

Implement systematic monitoring for fluoroquinolone resistance among gram-negative bacilli in your institution 1. This is an A-II recommendation and essential for antimicrobial stewardship.

Common Pitfalls to Avoid

1. Don't wait for fever to develop - prophylaxis is for afebrile patients at high risk
2. Don't use fluoroquinolones for empiric treatment if already on fluoroquinolone prophylaxis - if fever develops while on prophylaxis, switch to a different empiric regimen 1
3. Don't discontinue prophylaxis prematurely - continue until clear marrow recovery, not just when patient feels better
4. Don't add unnecessary gram-positive coverage - this increases resistance without proven benefit 1

Additional Considerations for B-cell ALL

The NCCN guidelines specifically categorize acute leukemia (including B-cell ALL) during induction and consolidation/maintenance as high-risk for infection, warranting fluoroquinolone prophylaxis during neutropenia 3. This reinforces the recommendation even more strongly for your patient.

Recent evidence shows that B-cell ALL patients, particularly those receiving novel therapies like blinatumomab, can experience significant neutropenia (41% experiencing grade ≥3 neutropenia) 4, further supporting the need for prophylaxis in this population.

If Fluoroquinolone Intolerance Exists

For patients intolerant to fluoroquinolones, consider:

• Trimethoprim-sulfamethoxazole (TMP/SMX), OR
• An oral third-generation cephalosporin 3

These are category 2B alternatives but less well-studied than fluoroquinolones.